Metabolic dysfunction-associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study

被引:0
|
作者
Cho, Tomonori [1 ]
Fukunaga, Shuhei [1 ]
Ohzono, Daiki [1 ]
Tanaka, Hiroshi [1 ]
Minami, Shinpei [1 ]
Nakane, Tomoyuki [1 ]
Mukasa, Michita [1 ]
Yoshinaga, Shinobu [2 ]
Nouno, Ryuichi [3 ]
Takedatsu, Hidetoshi [1 ]
Kawaguchi, Takumi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka, Japan
[2] Publ Util Fdn Saga Prefectural Hlth Promot Fdn, Med Examinat Sect, Med Examinat Part Facil, Saga, Japan
[3] Kumamoto City Hosp, Dept Gastroenterol, Kikuchi, Kumamoto, Japan
关键词
gallstone; hypertension; MASLD with moderate alcohol intake; metabolic dysfunction-associated steatotic liver disease; GALLBLADDER-DISEASE; GLOBAL BURDEN; CHOLELITHIASIS; EPIDEMIOLOGY; CHOLESTEROL; GUIDELINES;
D O I
10.1111/hepr.14170
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: Gallstone formation is associated with metabolic dysfunction. Recently, new definitions of steatotic liver disease (SLD) have been proposed, including metabolic dysfunction-associated SLD (MASLD) and moderate alcohol intake (MetALD). We investigated the effects of MASLD/MetALD on gallstone formation. Methods: This multicenter observational cohort study enrolled 8766 consecutive health-check examinees who underwent abdominal ultrasonography between 2008 and 2021 (total observation period 39,105.9 person-years). All patients were classified into non-SLD, MASLD, or MetALD groups. The effect of MASLD on gallstone development was evaluated using multivariate Cox regression analysis. Results: Age, male sex, and MASLD were identified as independent risk factors for gallstone development. MASLD was associated with a significantly higher risk of developing gallstones than non-SLD (hazard ratio [HR] 1.7112; 95% confidence interval [CI] 1.4294-2.0486; p < 0.0001) and MetALD (HR 1.3516, 95% CI 1.0130-1.8033, p = 0.0406). However, the risk of MetALD did not significantly differ between the SLD and non-SLD groups. Hypertension was the only significant independent cardiometabolic risk factor for gallstone development in the MASLD group (HR 1.4350, 95% CI 1.0545-1.9528; p = 0.0216). Random forest analysis and directed acyclic graphs identified hypertension as the most important direct factor affecting gallstone development in patients with MASLD. Conclusions: MASLD was an independent risk factor for gallstone development, whereas MetALD presented a similar risk as non-SLD. Moderate alcohol consumption may reduce the risk of gallstone formation in patients with MASLD. Hypertension may be the most significant cardiometabolic risk factor for gallstone development in patients with MASLD.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [2] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [3] Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study
    Baek, Ji Woo
    Yang, Yeun Soo
    Jung, Keum Ji
    Kimm, Heejin
    Kim, So Young
    Lee, Sunmi
    Jee, Sun Ha
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (12) : 2623 - 2629
  • [4] Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Chronic Periodontitis: A Nationwide Cohort Study
    Shine, Bo-Kyung
    Son, Minkook
    Moon, Sang Yi
    Han, Seong-Ho
    NUTRIENTS, 2025, 17 (01)
  • [5] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [6] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [7] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [8] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65
  • [9] Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study
    Li, Nan
    Liu, Chenbing
    Lu, Zhangfan
    Wu, Wenjian
    Zhang, Feng
    Qiu, Lihong
    Shen, Chao
    Sheng, Di
    Liu, Zhong
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [10] Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
    Vega, Luis
    Simian, Daniela
    Gajardo, Abraham I.
    Salinas, Marcelo
    Urra, Andrea
    Cattaneo, Maximo
    Pino, Rosario
    Roblero, Juan P.
    Urzua, Alvaro
    Rojas, Katherine
    Poniachik, Jaime
    ANNALS OF HEPATOLOGY, 2024, 29 (04)